NO20064982L - 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav - Google Patents

1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav

Info

Publication number: NO20064982L
Authority: NO; Norway
Prior art keywords: oxadiazole; ones; delta modulators; ppar delta; compounds
Prior art date: 2004-04-01

Application number

NO20064982A

Other languages

English (en)

Norwegian (no)

Inventor

Stefanie Keil

Jean Merrill

Karen Chandross

Jochen Goerlitzer

Wolfgang Wendler

Daniel G Mcgarry

Patrick Bernardelli

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-01

Filing date

2006-10-31

Publication date

2006-10-31

2006-10-31 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2006-10-31 Publication of NO20064982L publication Critical patent/NO20064982L/no

Links

WTSXVIMLKCKWIW-UHFFFAOYSA-N 3h-1,3,4-oxadiazol-2-one Chemical class O=C1NN=CO1 WTSXVIMLKCKWIW-UHFFFAOYSA-N 0.000 title abstract 2
108010015181 PPAR delta Proteins 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 3
208000016192 Demyelinating disease Diseases 0.000 abstract 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
230000004129 fatty acid metabolism Effects 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
239000008177 pharmaceutical agent Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Obesity (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Inks, Pencil-Leads, Or Crayons (AREA)

NO20064982A 2004-04-01 2006-10-31 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav NO20064982L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55841904P	2004-04-01	2004-04-01
PCT/US2005/010854 WO2005097762A2 (en)	2004-04-01	2005-03-30	1,3,4-oxadiazol-2-ones as ppar delta modulators

Publications (1)

Publication Number	Publication Date
NO20064982L true NO20064982L (no)	2006-10-31

Family

ID=34972933

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20064982A NO20064982L (no)	2004-04-01	2006-10-31	1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav

Country Status (17)

Country	Link
US (1)	US7576109B2 (de)
EP (1)	EP1735303B1 (de)
JP (1)	JP4813460B2 (de)
KR (1)	KR20060135854A (de)
CN (1)	CN100516065C (de)
AT (1)	ATE507226T1 (de)
AU (1)	AU2005230837A1 (de)
BR (1)	BRPI0509468A (de)
CA (1)	CA2561738A1 (de)
DE (1)	DE602005027677D1 (de)
IL (1)	IL178167A0 (de)
MA (1)	MA28562B1 (de)
NO (1)	NO20064982L (de)
NZ (1)	NZ550857A (de)
RU (1)	RU2375358C2 (de)
WO (1)	WO2005097762A2 (de)
ZA (1)	ZA200607851B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0508180A (pt) *	2004-04-01	2007-08-07	Aventis Pharma Inc	1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste
WO2005105736A1 (en)	2004-05-05	2005-11-10	Novo Nordisk A/S	Novel compounds, their preparation and use
ES2352085T3 (es)	2004-05-05	2011-02-15	High Point Pharmaceuticals, Llc	Nuevos compuestos, su preparación y uso.
ATE529404T1 (de)	2005-06-30	2011-11-15	High Point Pharmaceuticals Llc	Phenoxyessigsäuren als ppar-delta-aktivatoren
CA2624102A1 (en)	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
SI1931660T1 (sl) *	2005-09-29	2012-12-31	Sanofi	Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila
BRPI0620468A2 (pt)	2005-12-22	2011-11-08	Transtech Pharma, Inc.	ácidos fenóxi acéticos como ativadores de ppar delta
WO2007101864A2 (en)	2006-03-09	2007-09-13	High Point Pharmaceuticals, Llc	Compounds that modulate ppar activity, their preparation and use
US20080004281A1 (en) *	2006-06-28	2008-01-03	Kalypsys, Inc.	Methods for the modulation of crp by the selective modulation of ppar delta
US20120020931A1 (en) *	2010-06-02	2012-01-26	Rutgers, The State University Of New Jersey	Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
WO2015035171A1 (en)	2013-09-09	2015-03-12	High Point Pharmaceuticals, Llc	Use of a ppar-delta agonist for treating muscle atrophy
US20220387393A1 (en) *	2019-11-06	2022-12-08	Board Of Regents, The University Of Texas System	Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en)	2022-01-25	2023-08-03	Reneo Pharmaceuticals, Inc.	Use of ppar-delta agonists in the treatment of disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5103014A (en) *	1987-09-30	1992-04-07	American Home Products Corporation	Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4826990A (en) *	1987-09-30	1989-05-02	American Home Products Corporation	2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4895953A (en) *	1987-09-30	1990-01-23	American Home Products Corporation	2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5641796A (en) *	1994-11-01	1997-06-24	Eli Lilly And Company	Oral hypoglycemic agents
AU770870B2 (en) *	1999-06-18	2004-03-04	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) *	1999-06-25	1999-08-25	Glaxo Group Ltd	Chemical compounds
ATE260912T1 (de) *	1999-09-08	2004-03-15	Glaxo Group Ltd	Oxazol ppar antagonisten
JP4145230B2 (ja) *	2002-11-01	2008-09-03	武田薬品工業株式会社	神経障害の予防・治療剤
TW200505441A (en) *	2003-03-24	2005-02-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitorsⅠ
BRPI0508180A (pt) *	2004-04-01	2007-08-07	Aventis Pharma Inc	1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste

2005
- 2005-03-30 RU RU2006138485/04A patent/RU2375358C2/ru not_active IP Right Cessation
- 2005-03-30 AU AU2005230837A patent/AU2005230837A1/en not_active Abandoned
- 2005-03-30 CA CA002561738A patent/CA2561738A1/en not_active Abandoned
- 2005-03-30 EP EP05766888A patent/EP1735303B1/de not_active Expired - Lifetime
- 2005-03-30 CN CN200580010054.5A patent/CN100516065C/zh not_active Expired - Fee Related
- 2005-03-30 JP JP2007506540A patent/JP4813460B2/ja not_active Expired - Fee Related
- 2005-03-30 BR BRPI0509468-2A patent/BRPI0509468A/pt not_active IP Right Cessation
- 2005-03-30 NZ NZ550857A patent/NZ550857A/en unknown
- 2005-03-30 WO PCT/US2005/010854 patent/WO2005097762A2/en not_active Ceased
- 2005-03-30 AT AT05766888T patent/ATE507226T1/de not_active IP Right Cessation
- 2005-03-30 KR KR1020067020431A patent/KR20060135854A/ko not_active Ceased
- 2005-03-30 DE DE602005027677T patent/DE602005027677D1/de not_active Expired - Lifetime
2006
- 2006-09-18 IL IL178167A patent/IL178167A0/en unknown
- 2006-09-19 ZA ZA200607851A patent/ZA200607851B/en unknown
- 2006-09-26 US US11/535,227 patent/US7576109B2/en not_active Expired - Fee Related
- 2006-10-31 NO NO20064982A patent/NO20064982L/no not_active Application Discontinuation
- 2006-10-31 MA MA29428A patent/MA28562B1/fr unknown

Also Published As

Publication number	Publication date
WO2005097762A3 (en)	2005-12-15
RU2006138485A (ru)	2008-05-10
EP1735303B1 (de)	2011-04-27
US20070060626A1 (en)	2007-03-15
BRPI0509468A (pt)	2007-09-11
CA2561738A1 (en)	2005-10-20
CN100516065C (zh)	2009-07-22
ATE507226T1 (de)	2011-05-15
AU2005230837A1 (en)	2005-10-20
US7576109B2 (en)	2009-08-18
NZ550857A (en)	2009-12-24
DE602005027677D1 (de)	2011-06-09
WO2005097762A2 (en)	2005-10-20
IL178167A0 (en)	2006-12-31
JP4813460B2 (ja)	2011-11-09
MA28562B1 (fr)	2007-04-03
KR20060135854A (ko)	2006-12-29
EP1735303A2 (de)	2006-12-27
RU2375358C2 (ru)	2009-12-10
JP2007531763A (ja)	2007-11-08
CN1938305A (zh)	2007-03-28
ZA200607851B (en)	2008-06-25

Legal Events

Date	Code	Title	Description
2011-10-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
SG170101A1 (en)	2011-04-29	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
TW200728305A (en)	2007-08-01	Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
DK1689721T3 (da)	2010-09-20	Aminopyrazolderivater som GSK-3-ihibitorer
MX2008013836A (es)	2008-11-10	Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
EP1562897A4 (de)	2007-06-27	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
MXPA03011484A (es)	2004-03-18	Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NZ539841A (en)	2007-11-30	Hydroxyethylamine derivatives for the treatment of alzheimer's disease
EP1689713A4 (de)	2009-02-18	Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201170705A1 (ru)	2011-12-30	Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
CY1107956T1 (el)	2013-03-13	Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
NO20071042L (no)	2007-04-19	5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
WO2008030412A3 (en)	2008-11-20	Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006044497A3 (en)	2006-09-08	Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
NO20082496L (no)	2008-07-24	Pyrazinderivater
EP2091328A4 (de)	2010-11-03	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DK1641454T3 (da)	2009-02-09	Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
SG151336A1 (en)	2009-04-30	1,3,4-oxadiazol-2-ones as ppar delta
NO20064982L (no)	2006-10-31	1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
EP1817312A4 (de)	2009-11-04	Makrozyklische aminiopyridyl-beta-sekretase-hemmer zur behandlung von morbus alzheimer
DE602006009556D1 (de)	2009-11-12	Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
DE602005014629D1 (de)	2009-07-09	Pyrazolphenylderivate als ppar-aktivatoren